)
Visual
test
Adocia
Adocia (ADOC) investor relations material
Adocia Q4 2025 TU earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 TU earnings summary24 Feb, 2026
Executive summary
Positive Phase 3 results for BioChaperone® Lispro in both type 1 and type 2 diabetes in China, with marketing authorization filing in preparation and a $20M milestone payment pending approval.
Ongoing feasibility studies for BioChaperone® peptide stabilization and combination with two major pharmaceutical partners.
Patent filed for AdoXLong™ platform enabling once-monthly peptide injections for obesity and diabetes, with promising early results using semaglutide.
Leadership transition: Gérard Soula steps down as Chairman, succeeded by Stéphane Boissel, with Jacky Vonderscher joining as Director.
Financial highlights
FY 2025 revenue was €1.5M, mainly from a feasibility study on AdOral® technology; FY 2024 revenue was €9.3M, driven by a $10M milestone from Tonghua Dongbao.
Cash position at year-end 2025 was €17.2M, up from €7.5M at end-2024, bolstered by a €10M fundraising in December 2025.
Net financial debt (excluding IFRS 16) was €1.9M as of December 31, 2025, with loan maturity in August 2026.
Cash runway secured until early 2027, not accounting for potential future partnership revenues or warrant exercises.
Outlook and guidance
Cash reserves expected to fund operations through early 2027, with additional upside possible from new partnerships and warrant exercises.
Preparation underway for clinical trial application for AdoShell® Islets in Q3 2026.
M1Pram partnership discussions with Sanofi ongoing; clinical trial launch contingent on agreement.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Adocia
- Strong cash position, positive Phase 3 results, and advancing R&D drive future growth.ADOC
Q3 2025 TU15 Oct 2025 - Net loss of €9.3M in H1 2025, cash runway extended to Q2 2026 after capital raise and milestone.ADOCH1 202529 Sep 2025
- Cash position strengthened and pipeline progress set stage for key milestones in 2025.ADOCH1 2025 TU23 Jul 2025
- Innovative peptide delivery platforms advance late-stage diabetes and obesity treatments.ADOCInvestor Presentation27 Jun 2025
- Net loss stable at €8.9M; cash runway to Q3 2025; key diabetes programs advance.ADOCH1 202413 Jun 2025
- Q3 2024 closed with €9.3M cash, no revenue, and a $10M milestone expected in December.ADOCQ3 2024 TU13 Jun 2025
- Cash position rises to €13M, pipeline advances, and key partnerships progress amid sector headwinds.ADOCQ2 2024 TU13 Jun 2025
- Cash runway extended to Q2 2026 as Adocia advances diabetes and obesity programs.ADOCQ1 2025 TU6 Jun 2025
- Q4 revenue quadrupled year-over-year, fueled by a major milestone payment and robust pipeline progress.ADOCQ4 2024 TU6 Jun 2025
Next Adocia earnings date
H2 202521 Apr, 2026
Adocia
Next Adocia earnings date
H2 202521 Apr, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage